Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a bone marrow examination revealed increased myeloblasts, at which time computed tomography showed diffuse ground-glass opacities and interlobular septal thickening in the bilateral lower lung fields. A lung biopsy revealed the presence of PAP; therefore, the clinical diagnosis of MDS/sPAP was confirmed. Careful attention should be paid to the development of sPAP in MDS patients with pulmonary lesions during azacitidine treatment.
雑誌名
Internal Medicine
巻
59
号
8
ページ
1081 - 1086
発行年
2020-04-20
出版者
The Japanese Society of Internal Medicine
出版者別言語
日本内科学会
ISSN
09182918
EISSN
13497235
DOI
10.2169/internalmedicine.3770-19
権利
c 2020 The Japanese Society of Internal Medicine. The Internal Medicine is an Open Access journal distributed under license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome
IntMed59_1081.pdf
(1.85MB)
NAOSITEについて